Overview

A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old

Status:
Completed

Trial end date:
2013-07-01

Target enrollment:

Participant gender:

Summary

The main objective of this study is to compare conventional chemotherapy: daunorubicin and the Aracytine and this chemotherapy in combination with the monoclonal antibody used Mylotarg in divided doses.

Phase:

Phase 3

Details

Lead Sponsor:

Acute Leukemia French Association

Collaborator:

Versailles Hospital

Treatments:

Cytarabine
Daunorubicin
Gemtuzumab